![Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans | Journal of the American College of Cardiology Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/a7a9c084-1778-4d31-be40-8f54b1e8fbf2/gr4.jpg)
Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans | Journal of the American College of Cardiology
![Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations | JACC: Asia Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations | JACC: Asia](https://www.jacc.org/cms/asset/0d47f853-7999-4128-bcf9-ba0cff8111a4/gr4.jpg)
Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations | JACC: Asia
![Preferred ACS Treatment Not Associated With Better Patient Outcomes In Contemporary Clinical Practice According To Recent Multi-National Observational Study – OHDSI Preferred ACS Treatment Not Associated With Better Patient Outcomes In Contemporary Clinical Practice According To Recent Multi-National Observational Study – OHDSI](https://www.ohdsi.org/wp-content/uploads/2020/10/Chan-graphic.png)
Preferred ACS Treatment Not Associated With Better Patient Outcomes In Contemporary Clinical Practice According To Recent Multi-National Observational Study – OHDSI
![Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin | Stroke Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin | Stroke](https://www.ahajournals.org/cms/asset/777cc2ea-c195-4556-a749-3bb7ba764cc3/strokeaha.120.032239.fig03.jpg)
Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin | Stroke
![Cas(274693-27-5), Ticagrelor-Aladdin, AR-C 126532XX; AZD 6140;AZD6140;AZD-6140;(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol, Cas(274693-27-5), Ticagrelor-Aladdin, AR-C 126532XX; AZD 6140;AZD6140;AZD-6140;(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol,](https://www.aladdin-e.com/media/catalog/product/cache/49efc48ad39f6e70be72d36ea561a565/T/1/T125095.png)
Cas(274693-27-5), Ticagrelor-Aladdin, AR-C 126532XX; AZD 6140;AZD6140;AZD-6140;(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol,
![Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome | Circulation Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome | Circulation](https://www.ahajournals.org/cms/asset/d339bb41-532f-4a6c-bdbf-4215e7bd9085/circulationaha.120.050645.fig01.gif)